Related Experiment Videos

Inhibition of carcinogenesis by retinoids

Cancer Research
|May 1, 1983
PubMed

Insights

Retinoids show promise in preventing mammary and urinary bladder cancers in animals. Modified retinoids offer targeted cancer prevention with fewer side effects, even when treatment is delayed.

Area of Science:

  • Oncology
  • Chemoprevention
  • Carcinogenesis research

Background:

  • Retinoids are established chemopreventive agents against chemical carcinogenesis.
  • Experimental models demonstrate retinoid efficacy in mammary gland and urinary bladder cancer prevention.
  • Modifications to retinoid structures enhance target organ specificity and reduce toxicity.

Purpose of the Study:

  • To evaluate the efficacy of modified retinoids in cancer chemoprevention.
  • To investigate the synergistic effects of retinoid treatment combined with hormonal manipulation.
  • To determine the impact of delayed retinoid administration on chemopreventive activity.

Main Methods:

  • Administration of modified retinoids to experimental animals.
  • Combination therapy involving retinoids and hormonal manipulation.
  • Assessment of cancer incidence and development following carcinogenic insult and varying treatment delays.

Main Results:

  • Retinoids effectively inhibit mammary gland and urinary bladder carcinogenesis.
  • Modified retinoids exhibit increased anticancer activity and reduced systemic toxicity.
  • Combined retinoid and hormonal therapy synergistically inhibit mammary carcinogenesis.
  • Retinoid treatment remains effective even when initiated after the carcinogenic insult, with efficacy duration linked to tumor latency.

Conclusions:

  • Retinoids are potent chemopreventive agents for mammary and urinary bladder cancers.
  • Structural modifications and combination therapies enhance retinoid efficacy and safety.
  • Delayed retinoid administration is a viable strategy for cancer chemoprevention, particularly for tumors with long latency periods.

Related Concept Videos